XML 66 R30.htm IDEA: XBRL DOCUMENT v3.20.1
Business Segment, Geographic, and Concentration Risk Information (Tables)
3 Months Ended
Mar. 31, 2020
Segment Reporting [Abstract]  
Summary of Revenue by Segments

Segment information is as follows (in thousands):

 

 

 

Three Months

Ended March 31,

 

 

 

2020

 

 

2019

 

Total revenue:

 

 

 

 

 

 

 

 

Oncology Innovation Platform

 

$

28,387

 

 

$

144

 

Global Supply Chain Platform

 

 

3,714

 

 

 

11,339

 

Commercial Platform

 

 

15,542

 

 

 

14,675

 

Total revenue for reportable segments

 

 

47,643

 

 

 

26,158

 

Intersegment revenue

 

 

(708

)

 

 

(851

)

Total consolidated revenue

 

$

46,935

 

 

$

25,307

 

 

Summary of Revenue by Product Group

 

 

 

Three Months

Ended March 31,

 

 

 

2020

 

 

2019

 

Total revenue by product group:

 

 

 

 

 

 

 

 

License fees

 

$

28,381

 

 

$

 

Commercial product sales

 

 

17,502

 

 

 

20,081

 

API sales

 

 

1,022

 

 

 

4,831

 

Contract manufacturing revenue

 

 

23

 

 

 

251

 

Other revenue

 

 

7

 

 

 

144

 

Total consolidated revenue

 

$

46,935

 

 

$

25,307

 

 

Summary of Segment Information

 

 

 

Three Months

Ended March 31,

 

 

 

2020

 

 

2019

 

Net loss attributable to Athenex, Inc.:

 

 

 

 

 

 

 

 

Oncology Innovation Platform

 

$

(958

)

 

$

(27,603

)

Global Supply Chain Platform

 

 

(5,986

)

 

 

(767

)

Commercial Platform

 

 

(12,485

)

 

 

(6,863

)

Total consolidated net loss attributable to

   Athenex, Inc.

 

$

(19,429

)

 

$

(35,233

)

 

Summary of Depreciation, Amortization and Assets by Segment

 

 

Three Months

Ended March 31,

 

 

 

2020

 

 

2019

 

Total depreciation and amortization:

 

 

 

 

 

 

 

 

Oncology Innovation Platform

 

$

175

 

 

$

189

 

Global Supply Chain Platform

 

 

496

 

 

 

311

 

Commercial Platform

 

 

415

 

 

 

379

 

Total consolidated depreciation and

   amortization

 

$

1,086

 

 

$

879

 

 

 

 

March 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Total assets:

 

 

 

 

 

 

 

 

Oncology Innovation Platform

 

$

156,358

 

 

$

194,183

 

Global Supply Chain Platform

 

 

81,930

 

 

 

63,598

 

Commercial Platform

 

 

59,499

 

 

 

52,151

 

Total consolidated assets

 

$

297,787

 

 

$

309,932

 

 

Summary of Revenue by Geographical Segment

 

 

Three Months

Ended March 31,

 

 

 

2020

 

 

2019

 

Total revenue:

 

 

 

 

 

 

 

 

China

 

$

28,513

 

 

$

386

 

United States

 

 

17,522

 

 

 

20,335

 

India

 

 

 

 

 

777

 

Austria

 

 

 

 

 

2,173

 

United Kingdom

 

 

 

 

 

1,023

 

Other foreign countries

 

 

900

 

 

 

613

 

Total consolidated revenue

 

$

46,935

 

 

$

25,307

 

 

Summary of Property and Equipment by Geographical Segment

 

 

March 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Total property and equipment, net:

 

 

 

 

 

 

 

 

United States

 

$

12,467

 

 

$

11,486

 

China

 

 

12,149

 

 

 

11,667

 

Total consolidated property and equipment, net

 

$

24,616

 

 

$

23,153

 

 

Summary of Customer Revenue and Accounts Receivable Concentration

Customer revenue and accounts receivable concentration amounted to the following for the identified periods. These customers relate to the Commercial Platform segment and the Global Supply Chain Platform segment.

 

 

 

Three Months

Ended March 31,

 

 

 

2020

 

 

2019

 

Percentage of total revenue by customer:

 

 

 

 

 

 

 

 

Customer A

 

 

60

%

 

 

0

%

Customer B

 

 

11

%

 

 

22

%

Customer C

 

 

9

%

 

 

21

%

Customer D

 

 

7

%

 

 

12

%

 

 

 

March 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Percentage of total accounts receivable by customer:

 

 

 

 

 

 

 

 

Customer A

 

 

58

%

 

 

0

%

Customer B

 

 

14

%

 

 

45

%

Customer C

 

 

13

%

 

 

31

%

Customer D

 

 

8

%

 

 

10

%